Reading time ( words)
Insulet Corp. recently entered into a materials supplier agreement with Flextronics Medical Sales and Marketing Ltd. In a Securities and Exchange Commission (SEC) filing by Insulet, under the new agreement, which has an initial term of five years, Flextronics will continue to produce and manufacture Insulet's proprietary Omnipod Insulin Management System, as well as its drug delivery devices and personal diabetes managers (PDMs).
Flextronics will continue to manufacture the devices at its subsidiary's facility in China. Under the new agreement, Flextronics will supply Insulet with devices in accordance with rolling 12-month forecast and delivery schedules provided by the company, and the company will continue to purchase product on pricing and terms agreed by the parties.
The new agreement supersedes all prior agreements between Insulet and Flextronics, including the prior master supply and manufacturing services agreements entered into by the parties.